Linifanib (ABT-869) enhances radiosensitivity of head and neck squamous cell carcinoma cells.

[1]  P. Bisen,et al.  Induction of apoptosis and sensitization of head and neck squamous carcinoma cells to cisplatin by targeting survivin gene expression. , 2012, Current gene therapy.

[2]  Lin Wang,et al.  Targeting Stat3 Abrogates EGFR Inhibitor Resistance in Cancer , 2012, Clinical Cancer Research.

[3]  Jian-hua Zhou,et al.  Down‐regulation of Notch receptor signaling pathway induces caspase‐dependent and caspase‐independent apoptosis in lung squamous cell carcinoma cells , 2012, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[4]  R. Grafström,et al.  Combining factors on protein and gene level to predict radioresponse in head and neck cancer cell lines. , 2011, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[5]  Mei Zhao,et al.  Assembly and Initial Characterization of a Panel of 85 Genomically Validated Cell Lines from Diverse Head and Neck Tumor Sites , 2011, Clinical Cancer Research.

[6]  D. Hayes,et al.  Antitumor activity of enzastaurin as radiation sensitizer in head and neck squamous cell carcinoma , 2011, Head & neck.

[7]  S. Farag,et al.  The novel histone deacetylase inhibitor, AR‐42, inhibits gp130/Stat3 pathway and induces apoptosis and cell cycle arrest in multiple myeloma cells , 2011, International journal of cancer.

[8]  R. Kong,et al.  Inhibition of survivin expression and mechanisms of reversing drug-resistance of human lung adenocarcinoma cells by siRNA. , 2010, Chinese medical journal.

[9]  P. Bisen,et al.  Down-regulation of survivin by oxaliplatin diminishes radioresistance of head and neck squamous carcinoma cells. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[10]  Sang-Gu Hwang,et al.  Bcl‐XL and STAT3 mediate malignant actions of γ‐irradiation in lung cancer cells , 2010, Cancer science.

[11]  A. Joe,et al.  Stat3 orchestrates tumor development and progression: the Achilles' heel of head and neck cancers? , 2010, Current cancer drug targets.

[12]  Neeraj Gupta,et al.  Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  D. Bigner,et al.  Epidermal growth factor receptor variant III mediates head and neck cancer cell invasion via STAT3 activation , 2009, Oncogene.

[14]  L. Wilson,et al.  BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy , 2009, International journal of cancer.

[15]  B. Goh,et al.  ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside , 2009, Journal of hematology & oncology.

[16]  J. Bosq,et al.  Characterization of laryngeal carcinoma by confocal endomicroscopy , 2009 .

[17]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[18]  E. Livingston,et al.  In vitro and in vivo sensitization of SW620 metastatic colon cancer cells to CDDP-induced apoptosis by the nitric oxide donor DETANONOate: Involvement of AIF. , 2009, Nitric oxide : biology and chemistry.

[19]  R. Ralhan,et al.  Overview of current and future biologically based targeted therapies in head and neck squamous cell carcinoma , 2009, Head & neck oncology.

[20]  K. Glaser,et al.  ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft. , 2008, Journal of hepatology.

[21]  B. Liu,et al.  Activation of Signal Transducers and Activators of Transcription 3 and Overexpression of its Target Gene CyclinD1 in Laryngeal Carcinomas , 2008, The Laryngoscope.

[22]  C. Bokemeyer,et al.  Platinum-based chemotherapy plus cetuximab in head and neck cancer. , 2008, The New England journal of medicine.

[23]  A. Carvalho,et al.  Biological markers and prognosis in recurrent oral cancer after salvage surgery. , 2008, Archives of otolaryngology--head & neck surgery.

[24]  Jay Friedman,et al.  A signal network involving coactivated NF‐κB and STAT3 and altered p53 modulates BAX/BCL‐XL expression and promotes cell survival of head and neck squamous cell carcinomas , 2008, International journal of cancer.

[25]  J. Debus,et al.  Combination of Vascular Endothelial Growth Factor Receptor/Platelet-Derived Growth Factor Receptor Inhibition Markedly Improves Radiation Tumor Therapy , 2008, Clinical Cancer Research.

[26]  W. Mann,et al.  Impact of vascular endothelial growth factor release on radiation resistance. , 2007, Oncology reports.

[27]  G. Leitão,et al.  High-dose cisplatin concurrent to conventionally delivered radiotherapy is associated with unacceptable toxicity in unresectable, non-metastatic stage IV head and neck squamous cell carcinoma , 2007, European Archives of Oto-Rhino-Laryngology.

[28]  L. Giacomelli,et al.  Expression of the apoptosis inhibitor protein Survivin in primary laryngeal carcinoma and cervical lymph node metastasis. , 2006, Anticancer research.

[29]  A. Puisieux,et al.  Metastasis: a question of life or death , 2006, Nature Reviews Cancer.

[30]  Christopher U. Jones,et al.  Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. , 2006, The New England journal of medicine.

[31]  A. Garg,et al.  Chemosensitization and radiosensitization of tumors by plant polyphenols. , 2005, Antioxidants & redox signaling.

[32]  J. Greenman,et al.  Bcl-2 expression predicts radiotherapy failure in laryngeal cancer , 2005, British Journal of Cancer.

[33]  J. Licht,et al.  Therapeutic intervention in leukemias that express the activated fms-like tyrosine kinase 3 (FLT3): opportunities and challenges , 2005, Current opinion in hematology.

[34]  L. Zumstein,et al.  Enhancement of Ad‐p53 Therapy with Docetaxel in Head and Neck Cancer , 2004, The Laryngoscope.

[35]  Jacques Bernier,et al.  Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. , 2004, The New England journal of medicine.

[36]  J. Jacobs,et al.  Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. , 2004, The New England journal of medicine.

[37]  G. Semenza.  Angiogenesis in ischemic and neoplastic disorders. , 2003, Annual review of medicine.

[38]  J. Grandis,et al.  Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[39]  T. Greten,et al.  Stat3 and NF-κB activation prevents apoptosis in pancreatic carcinogenesis ☆ ☆☆ , 2002 .

[40]  P. Real,et al.  Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells , 2002, Oncogene.

[41]  R. Michalides,et al.  Overexpression of cyclin D1 enhances taxol induced mitotic death in MCF7 cells , 2002, Breast Cancer Research and Treatment.

[42]  R. Jove,et al.  Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[43]  J. Minna,et al.  Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. , 2000, Cancer research.

[44]  Hua Yu,et al.  Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells , 2004, Nature Medicine.